Analysts See $-0.71 EPS for Bellicum Pharmaceuticals, Inc. (BLCM); Nuveen Tax Advantaged Total Return Strategy Fund (JTA)’s Sentiment Is 1

April 17, 2018 - By Peter Erickson

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Logo

Analysts expect Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) to report $-0.71 EPS on May, 14.They anticipate $0.09 EPS change or 11.25% from last quarter’s $-0.8 EPS. After having $-0.61 EPS previously, Bellicum Pharmaceuticals, Inc.’s analysts see 16.39% EPS growth. The stock decreased 12.82% or $1.15 during the last trading session, reaching $7.82. About 2.47M shares traded or 135.37% up from the average. Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) has declined 43.51% since April 17, 2017 and is downtrending. It has underperformed by 55.06% the S&P500.

Nuveen Tax Advantaged Total Return Strategy Fund (JTA) investors sentiment decreased to 1 in Q4 2017. It’s down -0.12, from 1.12 in 2017Q3. The ratio fall, as 17 investment professionals increased and opened new holdings, while 17 reduced and sold their holdings in Nuveen Tax Advantaged Total Return Strategy Fund. The investment professionals in our database now possess: 1.65 million shares, down from 1.91 million shares in 2017Q3. Also, the number of investment professionals holding Nuveen Tax Advantaged Total Return Strategy Fund in top ten holdings was flat from 0 to 0 for the same number . Sold All: 3 Reduced: 14 Increased: 10 New Position: 7.

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company has market cap of $262.53 million. It has three product candidates in clinical development: BPX-501, an adjunct T-cell therapy product candidate being evaluated in Phase I/II clinical trials in children and adults following a T-depleted, haploidentical hematopoietic stem cell transplant ; BPX-601, a GoCAR-T product candidate in Phase I development for solid tumors expressing the prostate stem cell antigen; and BPX-701, a T cell receptors (TCR) product candidate in Phase I development for AML with future development potential for treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. It currently has negative earnings. The firm has collaboration agreements with Adaptimmune Therapeutics plc to evaluate, develop, and commercialize T-cell therapies; Ospedale Pediatrico Bambino Gesú for the design and development of various T cell immunotherapies; and Academisch Ziekenhuis Leiden for research to discover and validate high-affinity TCR product candidates targeting various cancer-associated antigens.

Among 11 analysts covering Bellicum Pharmaceuticals Inc (NASDAQ:BLCM), 10 have Buy rating, 1 Sell and 0 Hold. Therefore 91% are positive. Bellicum Pharmaceuticals Inc had 23 analyst reports since July 24, 2015 according to SRatingsIntel. Suntrust Robinson initiated the stock with “Buy” rating in Friday, June 3 report. The rating was maintained by Raymond James on Wednesday, August 9 with “Outperform”. The stock of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) earned “Sell” rating by Zacks on Monday, September 21. The firm has “Buy” rating by Jefferies given on Tuesday, August 9. Citigroup maintained Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) rating on Tuesday, August 9. Citigroup has “Neutral” rating and $24 target. The stock has “Outperform” rating by Wells Fargo on Thursday, April 12. The firm has “Buy” rating by SunTrust given on Friday, June 3. The stock has “Neutral” rating by Citigroup on Thursday, February 25. Jefferies maintained Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) on Monday, June 12 with “Buy” rating. Cantor Fitzgerald initiated the shares of BLCM in report on Wednesday, November 2 with “Buy” rating.

Nuveen Tax-Advantaged Total Return Strategy Fund is a closed-ended balanced mutual fund launched by Nuveen Investments, Inc. The company has market cap of $184.15 million. The fund is co-managed by Nuveen Fund Advisors, LLC, NWQ Investment Management Company, LLC, and Symphony Asset Management LLC. It has a 5.84 P/E ratio. It invests in the public equity and fixed income markets of the United States.

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Recent Posts